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The neuregulins (NRGs) play important roles in animal physiology, and their disregulation has been linked to diseases
such as cancer or schizophrenia. The NRGs may be produced as transmembrane proteins (proNRGs), even though they
lack an N-terminal signal sequence. This raises the question of how NRGs are sorted to the plasma membrane. It is also
unclear whether in their transmembrane state, the NRGs are biologically active. During studies aimed at solving these
questions, we found that deletion of the extracellular juxtamembrane region termed the linker, decreased cell surface
exposure of the mutant proNRGLinker, and caused its entrapment at the cis-Golgi. We also found that cell surface–
exposed transmembrane NRG forms retain biological activity. Thus, a mutant whose cleavage is impaired but is correctly
sorted to the plasma membrane activated ErbB receptors in trans and also stimulated proliferation. Because the linker is
implicated in surface sorting and the regulation of the cleavage of transmembrane NRGs, our data indicate that this region
exerts multiple important roles in the physiology of NRGs.
INTRODUCTION
The neuregulins (NRGs) are a group of polypeptide factors
that participate in several physiological processes such as
heart and peripheral nervous system development (Meyer
and Birchmeier, 1995; Britsch et al., 1998). Structurally, and
because of the presence of an epidermal growth factor
(EGF)-like module, these factors have been integrated into
the EGF family of transmembrane ligands, which also in-
cludes EGF, transforming growth factor- (TGF), amphi-
regulin, heparin-binding EGF (HB-EGF), betacellulin, epi-
regulin, and epigen (Massague´ and Pandiella, 1993; Harris et
al., 2003). These ligands are synthesized as membrane-
bound forms that can be solubilized by the action of cell
surface proteases, termed secretases (Blobel, 2005).
Four different NRG genes have been identified (Holmes et
al., 1992; Peles et al., 1992; Busfield et al., 1997; Carraway et
al., 1997; Chang et al., 1997; Zhang et al., 1997; Harari et al.,
1999). Complex alternative splicing of mRNAs produced by
these genes generates at least 15 different NRG isoforms
(Falls, 2003). Depending on the sequences found at their
N-terminal region, these isoforms have been grouped into
three different NRG types (Meyer et al., 1997; Falls, 2003).
Type I isoforms contain an N-terminal Ig-like domain; type
II contain an N-terminal kringle-like domain, followed by
the Ig-like domain; and type III contain an N-terminal hy-
drophobic domain within a cysteine-rich region (Meyer et
al., 1997; Falls, 2003). These divergent N-terminal regions are
followed by the EGF-like domain. In addition, the NRGs
may contain a linker (that includes a site for proteolytic
attack by cell surface secretases), an internal hydrophobic
sequence, and a C-terminal tail.
Type I NRGs are synthesized as larger transmembrane
molecules referred to as proNRGs, in homology to the pre-
cursor forms of other membrane-anchored growth factors of
the EGF family (Wen et al., 1994). Interestingly, and in con-
trast to the other EGF family factors, transmembrane type I
proNRGs lack an N-terminal signal sequence. This fact
raises the question of which domains of proNRGs are in-
volved in their membrane anchoring and proper cell surface
targeting.
The expression of type I NRGs as membrane bound fac-
tors also raises the interesting question of whether these
factors are active in their membrane-anchored form. Al-
though soluble forms of the EGF family factors have dem-
onstrated biological activity, the capacity of membrane-an-
chored forms to be functional is still controversial (Blobel,
2005). Thus, several in vitro studies indicated that mem-
brane-bound factors of the EGF family, including proTGF
(Brachmann et al., 1989; Wong et al., 1989; Anklesaria et al.,
1990; Baselga et al., 1996), proEGF, proNRG, or proHB-EGF,
retain biological activity in their transmembrane forms
(Dobashi and Stern, 1991; Higashiyama et al., 1995; Aguilar
and Slamon, 2001). Furthermore, membrane-anchored forms
of proTGF may activate the epidermal growth factor recep-
tor (EGFR) more efficiently than soluble forms of this growth
factor (Yang et al., 2000). However, results obtained using
other experimental models indicate that shedding is re-
quired for the action of membrane-bound factors. Thus,
metalloprotease inhibitors that prevent cleavage of mem-
brane-anchored factors blocked HB-EGF–mediated transac-
tivation of the EGF receptor (Prenzel et al., 1999) or reduced
proliferation and migration of breast epithelial cells express-
ing proTGF and proamphiregulin (Dong et al., 1999). Fur-
thermore, cells bearing inactive forms of TACE, a secretase
that cleaves proTGF (Peschon et al., 1998; Sunnarborg et al.,
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2002; Juanes et al., 2005), are unable to activate the EGFR in
vitro, and fail to generate tumors in nude mice (Borrell-
Pages et al., 2003). In addition, genetic data in flies (Golembo
et al., 1996) and mice (Yamazaki et al., 2003) have suggested
that release of membrane-anchored factors is required for
proper animal development. Therefore, shedding of mem-
brane-anchored growth factors may represent a rate-limiting
step in their biological action, at least when required at a
distance from their site of production.
The domain of proNRGs where shedding occurs is the
linker. This region ranges from 44 to 18 amino acids, de-
pending on the proNRG isoform (Fischbach and Rosen,
1997; Falls, 2003). Characterization of the cleavage sites in
the proNRG2c isoform indicated that cleavage occurs at the
Met-Lys-Val (MKV) microdomain within the linker region
(Lu et al., 1995). Deletion of the MKV sequence resulted in
resistance to ectodomain shedding of the proNRG2c
(Montero et al., 2000). These studies accompany others
(Wong et al., 1989; Hinkle et al., 2004; Singh et al., 2004) in
confirming the importance of the linker region in the regu-
lation of the cleavage efficiency of membrane-anchored
growth factors of the EGF family.
The fact that type I proNRGs are cell surface proteins but
lack an N-terminal signal sequence attracted us to investi-
gate the domains implicated in the membrane anchoring
and cell surface delivery of proNRGs. In addition, we
wanted to explore whether transmembrane proNRGs can be
biologically active. Here we report that the extracellular
juxtamembrane linker is required for efficient sorting of
proNRG2c to the plasma membrane. In addition, we dem-
onstrate that membrane-bound proNRG2c retains the ca-
pability to induce cell proliferation. Because the linker ap-
pears to be required for proper surface sorting, for the
regulation of the cleavage of transmembrane NRGs, and for
retention of the biological activity, our data indicate that this
region plays multiple important roles in the physiology of
NRGs.
MATERIALS AND METHODS
Reagents and Immunochemicals
Culture media, sera, and G418 were purchased from GIBCO BRL (Gaithers-
burg, MD). Protein A-Sepharose was from Amersham-Pharmacia (Piscat-
away, NJ). Immobilon-P membranes were from Millipore (Bedford, MA).
DAPI, brefeldin A, proteinase K, Protein A-HRP, tunicamycin, and doxycy-
cline were from Sigma Chemical (St. Louis, MO). BB3103 was generously
provided by British Biotech (Cowley, Oxford, United Kingdom). NHS-LC-
biotin was from Pierce (Rockford, IL). Mitotracker was from Molecular Probes
(Eugene, OR). Endoglycosidase H and N-glycosidase were from Roche Bio-
chemicals (Indianapolis, IN). Other generic chemicals were purchased from
Sigma Chemical, Roche Biochemicals, or Merck (Rahway, NJ).
The mouse monoclonal anti-PDI was from Stressgen (San Diego, CA). The
anti-actin antibody was from Sigma. Anti-HER3, anti-HER4 and anti-phos-
photyrosine were from Santa Cruz Biotechnology (Santa Cruz, CA). The
anti-pY1248, anti-pY1221/1222 and anti-pY877 that recognize phosphory-
lated ErbB2, and anti-pAkt were from Cell Signaling (Beverly, MA). The
anti-pY1139 was from Biosource International (Camarillo, CA). The antibod-
ies to GM130 and p230 were from BD Transduction (Lexington, KY). The Ab3
anti-ErbB2 antibody used for Western blotting was from Oncogene Science
(Manhasset, NY). The monoclonal anti-HER2 ectodomain antibody herceptin,
and soluble recombinant NRG were generously provided by Dr. Mark X.
Sliwkowski (Genentech, San Francisco, CA). The RKII anti-EGFR antibody
was generously provided by Dr. Joseph Schlessinger. The Cy3- or Cy2-
conjugated secondary antibodies were from Jackson ImmunoResearch (West
Grove, PA). HRP conjugates of anti-rabbit and anti-mouse IgG were from
Bio-Rad Laboratories (Cambridge, MA).
Anti-proNRG2c was raised against the sequence NH2-CETPDSYRSDPHSER-
COOH that corresponds to the 15 COOH-terminal residues of rat NRG2c
(Montero et al., 2000). For the generation of the anti-rat-NRG antibodies we
immunized rabbits with a GST fusion protein that included amino acids
19-181 of the proNRG2c, which corresponds to the ectodomain of this
protein.
Metabolic Labeling
Cells in 60-mm dishes were washed twice for 20 min each with methionine-
and cysteine-free DMEM and then were incubated in the same medium with
200 Ci/ml of a mixture of [35S]methionine and [35S]cysteine (Redivue Pro-
mix L-35S in vitro labeling mix, from Amersham). Incubations with the
radioactive medium proceeded for the times indicated in the figures, and then
medium was replaced by fresh medium. Cells were lysed and then immuno-
precipitated with the anti-proNRG antibody. Samples were run in 8% SDS-
PAGE gels that were dried and exposed to a autoradiographic film or to a
phosphorimager screen for quantitative analyses.
Cell Culture and Transfections
The conditions for the culture of MCF7 and 293 cells have been described
(Esparı´s-Ogando et al., 1999). Transfections in MCF7 or 293 cells were
performed by calcium phosphate, and clones were selected by G418. Single
clones were analyzed for their content of proNRG forms by Western
blotting with the anti-proNRG antibody. The proNRG2c-TetOff and the
TACEZn/Zn-NRG2c cells have been described in Yuste et al. (2005), and
Montero et al. (2000).
Plasmids and Construction of Mutants
The different forms of rat NRG2c were subcloned into KpnI/NotI sites of the
pCDNA3 vector (Invitrogen, Carlsbad, CA). The different deletions in the
juxtamembrane region of proNRG2c were generated by site directed mu-
tagenesis (MKV mutant) or PCR (rest of mutants) as described (Montero et al.,
2000). The Ig-like domain deletion (amino acids 19–177) was created by
digestion with BamHI. Mutants of proNRG2c were verified by automated
sequencing.
For the swapping of the linker of proNRG2c for a corresponding
sequence of the juxtamembrane region of the EGFR or ErbB2, these regions
were amplified using the following oligonucleotides: forward egfr linker
5-CCGGAATTCTGCACTGGGCCAGGT-3, reverse egfr linker 5-CCGGAAT-
TCGGACGGGATCTTAGG-3; forward erbb2 linker 5-CCGGAATTCGTG-
GACCTGGATGAC-3, reverse erbb2 linker 5-CCGGAATTCCGTCAGAG-
GGCTGGC-3. PCR amplification using these primers generated fragments
that were digested with EcoRI and subcloned into pCDNA3-proNRG2c in
which the linker was deleted by PCR, at the time that an EcoRI site was placed
to allow the subcloning of the linkers of EGFR and ErbB2.
Immunoprecipitation and Western Blotting
Cells were washed with PBS and lysed in ice-cold lysis buffer (140 mM NaCl,
10 mM EDTA, 10% glycerol, 1% Nonidet P-40, 20 mM Tris, pH 7.0, 1 M
pepstatin, 1 g/ml aprotinin, 1 g/ml leupeptin, 1 mM PMSF, and 1 mM
sodium orthovanadate). After scraping the cells from the dishes, samples
were centrifuged at 10000  g at 4°C for 10 min, and supernatants were
transferred to new tubes with the corresponding antibody and protein A-
Sepharose. Immunoprecipitations were performed at 4°C for at least 2 h, and
the immune complexes were recovered by a short centrifugation followed by
three washes with 1 ml of cold lysis buffer. Samples were then boiled in
electrophoresis sample buffer and loaded in SDS-PAGE gels. The rest of the
Western blotting procedure was as described (Cabrera et al., 1996).
For cell surface immunoprecipitation, cells in 100-mm dishes were washed
twice with Krebs-Ringer-HEPES buffer (KRH; Cabrera et al., 1996) and then
incubated for 2 h at 4°C with 4 l of anti-NRG antibody in 1 ml of KRH.
Monolayers were washed twice with PBS and lysed. Cell debris was removed
by centrifugation at 10,000 g at 4°C for 10 min, and supernatants transferred
to new tubes with protein A-Sepharose.
Proteinase Protection Experiments, Cell Surface
Biotinylation, and Cell Fractionation
Proteinase K protection experiments were carried out as described (Cabrera et
al., 1996). Briefly, cells were washed once with KRH buffer and then incubated
in this buffer supplemented with 200 g/ml proteinase K for 30 min. Cells
were then washed three times with PBS containing 2 mM PMSF and lysed in
1 ml of lysis buffer with protease inhibitors. Analyses of the effect of protein-
ase K on the different mutants and wild-type proNRG2c were carried out by
Western blotting using anti-proNRG.
For cell surface biotinylation, cells were washed twice with ice-cold KRH
and then incubated with NHS-LC-biotin (100 g/ml) for 2 h at 4°C. Cells were
washed again with KRH and then incubated with KRH containing 10 mM
glycine for 15 min at 4°C. Cell monolayers were washed and lysed, and the
lysates were precipitated with streptavidin agarose. Samples were run in 12%
SDS-PAGE gels and analyzed by Western blotting with the anti-proNRG
antiserum.
For the cell fractionation experiments (Massague, 1983), cells from 10
100-mm dishes (90% confluent) were washed with PBS and detached by
incubation for 10 min at 37°C with 0.25 M sucrose, 1 mM EDTA, 1 mM PMSF,
and 10 mM Tris, pH 7.0. The cell suspension was homogenized on ice with a
tight-fitting Dounce homogenizer. This homogenate was centrifuged at
4000  g for 10 min, and the resulting pellet was rehomogenized and centri-
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fuged at the same speed. The supernatants from these two centrifugation
steps were pooled and centrifuged at 30,000  g for 30 min. The supernatant
was taken as the cytosolic fraction. The resulting pellet was resuspended in
homogenization buffer, layered on top of a 36% (wt/wt) sucrose solution, and
centrifuged at 100,000  g for 60 min. The fraction of membranous material at
the 36% interface was collected, sedimented at 30,000  g for 30 min, and
resuspended in lysis buffer. This fraction corresponds to the plasma mem-
brane. The pellet obtained by centrifugation throughout the sucrose cushion
was taken as the microsomal nonplasma membrane fraction.
In Vitro Deglycosylation Experiments
Protein precipitates were solubilized by boiling for 5 min in 10 l of 0.25%
(wt/vol) SDS, and 0.1 M -2-mercaptoethanol. Then, 4 mU of endoglycosi-
dase H and 0.5 g of each of the protease inhibitors were added in 20 l of 50
mM sodium phosphate buffer (pH 5.8) and incubated at 37°C for 18 h.
Digestions were terminated by adding an equal volume of Laemmli sample
buffer and heating for 5 min at 100°C. The digestion products were separated
by SDS-PAGE and analyzed by Western blotting as above.
Cell Proliferation
Conditions for the analysis of the proliferation of MCF7 cells and derived
clones have been reported (Esparis-Ogando et al., 2002). Cells were plated at
20,000 cells/well and cultured overnight in DMEM  10% FBS. The next day
(day 1 of culture) cells were shifted to serum-free media, and an MTT assay
was performed and considered the starting point. MTT uptakes were mea-
sured at the times indicated in the figure legends.
Immunofluorescence Experiments
Cells cultured on glass coverslips were washed with PBS and fixed in 2%
p-formaldehyde for 30 min at room temperature, followed by two rinses in
PBS. To follow mitochondrial staining, 100 nM of Mitotracker Red (Molecular
Probes) was added for 20 min before fixing with p-formaldehyde. Monolayers
were then washed twice, for 10 min each time, with PBS supplemented with
0.1% (final concentration) Triton X-100 and then blocked in PBS with 0.2%
BSA for 20 min at room temperature. The immunofluorescence protocol has
been described (Esparis-Ogando et al., 2002).
Quantitative Estimation of proNRG Forms
Quantitation of the different proNRG in Western blots was performed by
using the NIH Image 1.61 software. To graphically represent the values of
each band (80 and 70–72-kDa forms for proNRG2c, the intensity of each
band was measured densitometrically. Then the sum of the bands was taken
as 100%, and the percentage intensity of each band with respect to the total of
that sample, or the control lane was calculated and plotted. Data show the
mean  SD for three different experiments.
RESULTS
Different Subcellular Distribution of proNRG2c Forms
This study was initiated with the purpose of evaluating the
domains of proNRG that are required for efficient sorting to
the plasma membrane. As a model we used proNRG2c, a
member of the type I subfamily of NRGs (Wen et al., 1994;
Falls, 2003). The extracellular region of this NRG contains an
N-terminal Ig-like domain followed by an EGF-like module,
the linker region, and the transmembrane and intracellular
domains (Figure 1A).
We analyzed the molecular forms and subcellular location
of proNRG2c using 293 cells transfected with a cDNA
coding for rat proNRG2c. In 293-NRG2c cells, Western
Figure 1. Forms and subcellular distribution of
proNRG2c. (A) Schematic representation of the differ-
ent domains of proNRG2c. The sites recognized by the
antibodies are shown. (B) Expression of proNRG2c in
293 cells. Cells transfected with the cDNA coding for
proNRG2c (293-NRG2c) were lysed, and samples im-
munoprecipitated with anti-endodomain or anti-NRG
antibodies. Immunoprecipitates were analyzed by
Western blotting with the anti-endodomain antibody.
The right panel is an overexposure of the left panel. The
position of the Mr markers is shown at the right. (C)
Immunofluorescence analysis of the subcellular distri-
bution of proNRG2c. 293-NRG2c cells were plated on
coverslips and stained with the anti-proNRG antibody.
Bar, 20 m. (D) Pulse-chase experiment of proNRG2c.
293-NRG2c cells were metabolically labeled for 30 min
and then chased for the indicated times. Lysates were
immunoprecipitated with the anti-proNRG antibody,
and the precipitates were analyzed in an 8% SDS-PAGE
gel followed by autoradiography. (E) Endoglycosidase
analysis of proNRG2c. 293-NRG2c cells were treated
with or without tunicamycin (10 g/ml) overnight,
lysed, and subjected to immunoprecipitation with the
anti-proNRG antibody. Where indicated the immuno-
complexes were digested with endoglycosidase H and
analyzed in 8% SDS-PAGE gels. The blot was probed
with the proNRG antibody. (F) Protease protection ex-
periments of proNRG2c. Cells were treated with pro-
teinase K, lysed, and subjected to immunoprecipitation
and Western blotting with the anti-proNRG. (G) Cell
surface immunoprecipitation of proNRG2c. 293-
NRG2c cells were incubated with the anti-NRG anti-
body and lysed, and surface-bound antibody was pre-
cipitated with protein A-Sepharose. The Western blot
was probed with the anti-proNRG antibody. (H) Cell
surface biotinylation of proNRG2c. Cells were incu-
bated with or without NHS-LC-biotin, and lysates were
precipitated with streptavidin agarose. The blot was
probed with the anti-proNRG antibody.
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blotting with the anti-proNRG antibody, that recognizes the
intracellular C-terminus of proNRG2c (Montero et al.,
2000), which identified a major band that migrated with an
apparent Mr of 80 kDa (p80), together with two less abun-
dant bands with apparent Mr of 70 and 72 kDa (p70 and p72,
respectively; Figure 1, B and D). These latter two bands
migrated very closely and were sometimes difficult to dif-
ferentiate from each other. The three bands corresponded to
proNRG2c as indicated by the failure of the antibody to
recognize analogous bands in parental 293 cells (Figure 1B).
On longer exposure times of the blots, the anti-endodomain
antibody also recognized lower Mr forms (Figure 1B, right
panel). These forms correspond to cell-bound tail fragments
generated upon cleavage of proNRG2c at the extracellular
domain (Montero et al., 2000). The 80-, 70-, and 72-kDa forms
contained the EGF-like NRG domain, as indicated by their
reactivity with an antibody raised to a GST fusion protein
that contained the NRG domain of proNRG2c (Figure 1B).
This anti-NRG antibody, however, failed to immunoprecipi-
tate the lower Mr tail fragments, indicating that these forms
were devoid of the EGF-like domain of NRG (Figure 1B,
right panel). Analogous results were obtained in CHO cells
expressing proNRG2c (data not shown; Montero et al.,
2000).
Immunofluorescence experiments in 293-NRG2c cells
stained with the anti-proNRG2c antibody indicated that
proNRG2c accumulated at two different sites: the cell sur-
face and an intracellular perinuclear site (Figure 1C). Anal-
ogous results were obtained by analyzing the distribution of
proNRG2c-GFP in which the C-terminus of proNRG2c
was fused to GFP (data not shown). The presence of multiple
proNRG2c forms, together with the immunofluorescence
data raised the possibility that different proNRG2c forms
could be located at distinct cellular sites. To explore this
Figure 2. Intracellular proNRG2c colocalizes with Golgi markers. (A) Colocalization of proNRG with the Golgi marker GM130. Immu-
nofluorescence was carried out as described in Materials and Methods. Bar, 20 m. (B) Immunofluorescence images showing the distribution
of proNRG2c, PDI, and the mitochondrial stain Mitotracker. Bar, 20 m. (C) Colocalization of proNRG with the cis-Golgi marker GM130
but not with the trans-Golgi marker p230. Cells treated with brefeldin A were analyzed by immunofluorescence with anti-GM130, anti-p230,
and anti-proNRG antibodies. Bar, 5 m. (D) Cell fractionation experiments of proNRG2c. Cells were fractionated as described in Materials
and Methods and analyzed for proNRG, EGFR, and actin by Western blotting.
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possibility, we performed several types of experiments. As
an initial step, we followed the biosynthesis of p80, p72, and
p70 by pulse-chase analyses. Cells were metabolically la-
beled for 30 min with 35S-amino acids and then chased for
different times. At the earliest time point analyzed, p70 and
p72 were clearly labeled (Figure 1D). These bands were then
rapidly chased to the 80-kDa form, whose amount reached a
maximum by 1 h of chase. At this latter time point the
amount of p70 and p72 was already very low. These data
indicate that p70 and p72 may represent immature
proNRG2c forms that chase into an 80-kDa more mature
form.
To gain further insights into the nature of the p80, p72,
and p70 forms, we explored their glycosylation status. Treat-
ments that prevented N-linked glycosylation in vivo (tuni-
camycin, Figure 1E) or enzymatically removed N-linked
sugars in vitro (N-glycosidase; data not shown) provoked
disappearance of the p72 form and a decrease in the appar-
ent Mr of the p80 form. We also used endoglycosidase H
(Endo H), which has been used to study the topological
location of glycosylated proteins while en route to the
plasma membrane. This glycosidase is active on high man-
nose oligosaccharides present in proteins in their early steps
of N-linked maturation. However, when the N-glycosylated
protein moves through the Golgi, the trimming of two man-
noses by Golgi mannosidase II, together with the addition of
other sugars, generates a complex oligosaccharide that is
resistant to the action of Endo H. Enzymatic deglycosylation
with Endo H also caused disappearance of p72. However,
the p80 form was resistant to Endo H. The different sensi-
tivity of p72 and p80 was taken as an indication that distinct
proNRG2c forms resided at different subcellular sites.
Treatment with Endo H did not apparently affect the p70
form, indicating that this form did not contain N-linker
sugars or had already moved to a subcellular compartment
where additional maturation of sugar chains created a com-
plex glycoprotein resistant to Endo H.
To investigate whether p80, p72, and 70 kDa forms were
exposed at the plasma membrane, we first analyzed their
sensitivity to protease K. Exposure of intact cells to the
protease caused disappearance of p80, but did not change
the amount of p72 or p70 (Figure 1F). As expected, protease
K treatment caused accumulation of the cell-associated tail
fragments that result from the degradation of the ectodo-
Figure 3. The linker region of proNRG2c
facilitates transit through the Golgi. (A) Sche-
matic representation of the deletion of the
linker of proNRG2c. (B) Protease protection
experiments of the proNRGLinker. Cells were
treated with protease K and lysed, and the
extracts were subjected to immunoprecipita-
tion and Western blotting with the anti-
proNRG antibody. The histogram shown is a
quantitation of the intensity of the bands of 80
and 70–72 kDa. The percentage is calculated
with respect to the total signal of the control
lane. The results represent the mean  SD of
three different experiments. (C) Expression of
proNRGIg in 293 cells and its sensitivity to
protease K. The position of the mature and
immature forms of this mutant are indicated
by asterisks. (D) Immunoprecipitation of
proNRG2c or proNRGLinker with the anti-
NRG antibody, followed by Western blotting
with the anti-NRG antibody. (E) Immunoflu-
orescence analysis of the subcellular distribu-
tion of proNRG2c and proNRGLinker mu-
tant. Bar, 20 m. (F) Colocalization of the
proNRGLinker mutant with the Golgi marker
GM130. Monolayers were fixed, permeabil-
ized, and incubated with anti-proNRG, anti-
GM130, or anti-PDI antibodies. Images were
captured using a Zeiss LSM510 confocal mi-
croscope. Bar, 20 m.
J. C. Montero et al.
Molecular Biology of the Cell384
main of proNRG2c. In cell surface immunoprecipitation
experiments, the anti-NRG antibody precipitated the 80-kDa
form, further supporting that this form was exposed at the
cell surface (Figure 1G). That the 80-kDa form was the only
proNRG2c form exposed at the plasma membrane was
further confirmed by surface biotinylation experiments (Fig-
ure 1H).
Colocalization experiments using antibodies to different
intracellular compartments indicated that intracellular
proNRG2c was mainly present in the Golgi, because the
proNRG2c staining colocalized with the cis-Golgi marker
GM130 (Figure 2A). In contrast, little proNRG2c immuno-
reactivity colocalized with the endoplasmic reticulum (ER)
marker PDI and none with the mitochondrial stain mito-
tracker (Figure 2B). Staining with the anti-proNRG endodo-
main antibody was coincident with that of GM130 (Figure
2C), but not with the trans-Golgi marker p230, indicating
that the intracellular accumulation observed in these cells
corresponds to proNRG2c that is present at the cis-Golgi.
In cell fractionation experiments the plasma membrane–
enriched fraction mainly contained the p80 form, together
with the lower Mr cell-associated tail fragments (Figure 2D).
Little amounts of p70 and p72 kDa were detected. The rest of
the microsomal fraction mainly contained the p70 and p72
kDa forms, together with a smaller amount of the lower Mr
cell-associated fragments. Also, some p80 was present, as
well as the 170-kDa EGFR, likely indicating that the micro-
somal fraction contained a small amount of plasma mem-
brane–derived microsomes (Figure 2D).
Taken together, these data indicate that proNRG2c is
expressed as several Mr forms, one of 80 kDa that is exposed
at the cell surface and less abundant forms of 70 and 72 kDa
that are located intracellularly, mainly at the cis-Golgi appa-
ratus.
Deletion of the Linker Causes Intracellular Entrapment of
pro-NRG2c
We searched for domains that regulate proNRG2c sorting by
performing deletions in various regions of proNRG2c. In 293
cells expressing a deletion of the linker (proNRGLinker mutant;
Figure 3A), we observed that the pattern of the proNRG forms
was inverted with respect to wild-type proNRG2c (Figure
3B). Thus, although in the wild type the major proNRG2c
form corresponded to p80, in the proNRGLinker mutant the
most abundant form corresponded to a band that migrated in
the 70-kDa region. This inverted pattern was also confirmed by
metabolic labeling of 293 cells expressing wild-type or the
proNRGLinker mutant (data not shown). Because of the dele-
tion of the linker, the Mr of the proNRGLinker forms was
slightly smaller than that of the wild-type forms. However, for
better understanding, we refer to them as p80 and p70, for the
slower and faster migrating forms, respectively. Protease pro-
Figure 4. Analysis of the linker region of proNRG2c.
(A) Pulse-chase analyses of proNRG2c and the
proNRGLinker mutant. Cells were labeled with 200
Ci/ml of a mixture of [35S]cysteine and [35S]methi-
onine for 20 min, and then the medium was replaced by
fresh, complete medium. Cells were lysed at the indi-
cated times. The extracts were immunoprecipitated
with the anti-proNRG antibody and analyzed in 8%
SDS-PAGE gels, followed by autoradiography. The
graphics below the gel shown the percent intensity of
each band with respect to the sum of the signal corre-
sponding to the 70–72-plus 80-kDa bands. (B) Effect of
brefeldin A on proNRG2c and proNRGLinker mutant.
293-NRG2c and 293-NRGLinker cells were treated
with or without brefeldin A (10 g/ml) overnight and
lysed. The extracts were subjected to immunoprecipita-
tion and Western blotting with the anti-proNRG anti-
body. (C) Endoglycosidase analysis of proNRGLinker
mutant. 293-NRGLinker cells were treated with or with-
out tunicamycin (10 g/ml) overnight, lysed, and sub-
jected to immunoprecipitation with the anti-proNRG
antibody. Where indicated the immunocomplexes were
digested with Endo H and analyzed by Western blot
with the proNRG antibody. (D) Analysis of the role of
N-linked glycosylation in the sorting of proNRG2c
and proNRGLinker. Cells were preincubated with or
without tunicamycin (10 g/ml, 12 h) and, where indi-
cated, treated with proteinase K. The immunoprecipita-
tion and Western blotting were as above.
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Figure 5. Analysis of different mutants of the linker region of proNRG2c. (A) Description of the sequences deleted or substituted in the
different mutants of the linker region of proNRG2c. (B) Expression of the different mutants of the linker region of proNRG2c. Cells
expressing the different mutants of the linker region were lysed, and samples were immunoprecipitated and analyzed by Western blot with
anti-proNRG antibody. The histogram at the right is a quantitation of the percent intensity of the 80-kDa band, with respect to the total signal
that comes from the sum of the p80, p72, and p70 bands. The results represent the mean  SD of three different experiments. (C) Protease
protection experiments of the different mutants of the linker region of proNRG2c. (D) Expression of mutants in which the linker region
of proNRG2c has been substituted by juxtamembrane sequence of EGFR or ErbB2 in 293 cells. Cells were lysed and analyzed by
immunoprecipitation and Western blot with anti-proNRG antibody.
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tection experiments indicated that the faster migrating form of
proNRGLinker was largely insensitive to proteinase K,
whereas the slower migrating form disappeared in cells treated
with the protease (Figure 3B). Cell fractionation experiments
performed in 293-NRGLinker cells confirmed that most of the
faster migrating form of proNRGLinker was retained within
the microsomal nonplasma membrane fraction (data not
shown). We analyzed whether deletion of other extracellular
regions could also provoke a similar accumulation of the faster-
migrating forms. To this end, we performed a deletion of the
entire Ig-like domain of proNRG2c. As shown in Figure 3C,
deletion of this region resulted in a significantly faster electro-
phoretic mobility of the proNRGIg form. However, this form
resembled wild-type proNRG2c in terms of relative abun-
dance of the mature and immature forms and of sensitivity to
protease K. We also evaluated whether shortening of the linker
could provoke gross misfolding of the EGF-like domain by
analyzing the immunoreactivity of the core NRG domain with
the anti-NRG antibody, which recognizes native NRG and can
block the biological activity of soluble NRG (R. Rodrı´guez-
Barrueco and A. Pandiella, unpublished observations). This
antibody precipitated both wild-type and proNRGLinker
forms in an analogous manner (Figure 3D).
Immunofluorescence experiments indicated differences in
the subcellular distributions of the wild-type and the
proNRGLinker mutant (Figure 3E). As expected from the
protease K protection experiments, the plasma membrane
staining of the proNRGLinker mutant was weak, whereas
the intracellular staining was substantially increased with
respect to wild-type proNRG2c (Figure 3E). Most of the
proNRGLinker colocalized with the GM130 Golgi marker
(Figure 3F), even though a small amount also appeared to
codistribute with PDI.
To biochemically evaluate the cellular site where
proNRGLinker was trapped, we performed several types of
experiments. First, we analyzed whether defects in the bio-
synthesis of proNRGLinker could explain its intracellular
retention. Cells were metabolically labeled for 20 min and
then chased for different times. As shown above, wild-type
proNRG2c was initially present as two forms of 70 and 72
kDa that were rapidly chased into the 80-kDa form (Figure
4A). In 293-NRGLinker cells the bands in the 70-kDa region
chased very poorly into the mature form. In these cells, the
early biosynthetic steps included two diffuse bands that
were chased to another band of intermediate Mr (arrow in
Figure 4A). The presence of the latter was obvious at 40 min
of chase and lasted for the entire duration of the experiment.
Quantitative analyses supported that the faster migrating
forms of proNRG2c chased into the mature 80-kDa form,
whereas the faster migrating form of proNRGLinker ineffi-
ciently chased into the mature form (Figure 4A, bottom
graphics).
We used brefeldin A to trap proNRG2c and proNRGLinker
in their early steps of biosynthesis. This treatment caused
accumulation of a diffuse band close to the p80 form (Fig-
ure 4B). This pattern was indistinguishable between the
proNRG2c and proNRGLinker mutant, suggesting, to-
gether with the metabolic labeling data, that the deficient
proNRGLinker sorting probably occurred beyond the early
biosynthetic steps. Tunicamycin and Endo H experiments
indicated that the faster migrating form of proNRGLinker
was N-glycosylated and resided in an Endo H-sensitive
compartment (Figure 4C). The p80 proNRGLinker form was
resistant to Endo H, indicating that this form had moved
away from the ER/cis-Golgi. Interestingly, tunicamycin
treatment did not prevent cell surface exposure of the slower
migrating form in both wild-type and proNRGLinker mu-
tant (Figure 4D), indicating that N-linked glycosylation is
dispensable for membrane sorting of proNRG2c.
We next addressed whether the primary sequence present
in the linker was critical for the surface targeting of
proNRG2c. To this end, we used several proNRG2c mu-
tants that included different deletions in the linker region
(Figure 5A). Partial deletions of the linker caused an increase
in the 70-kDa bands (Figure 5B), with independence of
whether they were performed C-terminal to the NRG do-
main, or N-terminal to the transmembrane domain (Figure
5A). Protease protection experiments carried out on cells
expressing these different mutants indicated that, in fact, the
higher Mr form of proNRG2c in the different mutants was
mainly cell surface exposed (Figure 5C). The only mutant
that behaved analogously to the wild-type form was the
proNRGMKV form (Figure 5, B and C).
We also substituted the proNRG2c linker for two unre-
lated sequences of the juxtamembrane extracellular region of
the EGFR or the ErbB2 receptor tyrosine kinase (Figure 5A).
Transient transfection experiments (Figure 5D) as well as
analyses of individual clones (data not shown) indicated anal-
ogous patterns of expression of the chimeric proteins and wild-
type proNRG2c. Furthermore, proteinase K protection ex-
Figure 6. Biological activity of the proNRGLinker mutant. (A) Ex-
pression of proNRG2c and the proNRGLinker mutant in MCF7
cells. MCF7 cells expressing proNRG2c (MCF7-NRG2c) or
proNRGLinker mutant (MCF7-NRGLinker) were lysed, immunopre-
cipitated, and blotted with the anti-proNRG antibody. (B) Prolifer-
ation of MCF7, MCF7-NRG2c, and MCF7-NRGLinker cells. Cells
were plated in 24-well plates and allowed to attach in complete
medium for 12 h, before switching to serum-free medium with or
without 10 nM NRG. MTT uptake was measured 5 d later. The
results show the mean SD of quadruplicates of an experiment that
was repeated four times. (C) Detection of soluble NRG in the
conditioned media. Conditioned media from MCF7, MCF7-
NRG2c, and MCF7-NRGLinker was concentrated 10-fold and then
analyzed by Western blot using the anti-NRG antibody (top panel).
In the experiment shown in the lower panel, MCF7 cells were
treated with conditioned media from MCF7, MCF7-NRG2c, and
MCF7-NRGLinker cells and then lysed. Samples were immunopre-
cipitated with an anti-ErbB2 antibody, and the blot was probed with
anti-phosphotyrosine antibodies. The position of tyrosine phos-
phorylated ErbB2 is shown.
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periments confirmed that these linker chimeric proteins
reached the plasma membrane in a manner indistinguish-
able from the wild-type proNRG2c (data not shown).
Therefore, the proper sorting of proNRG2c to the plasma
membrane does not appear to depend on the strict primary
sequence of the proNRG2c linker.
Biological Activity of Wild-Type pro-NRG2c and the
pro-NRGLinker Mutant
Intracellular forms of EGF have been shown to activate the
EGFR intracellularly, a phenomenon termed intracrine stim-
ulation (Wiley et al., 1998; Dong et al., 2005). To investigate
whether intracellular proNRG behaved analogously, we
used a cellular model based on MCF7 cells. These cells
express low-to-normal levels of the ErbB2, ErbB3, and ErbB4
receptor tyrosine kinases and mitogenically respond to the
addition of exogenous soluble NRG (Holmes et al., 1992;
Agus et al., 2002). Transfection of the cDNAs coding for
proNRG2c and proNRGLinker in MCF7 cells resulted in
the isolation of several clones that expressed these proNRG
peptides (Figure 6A). The molecular forms of proNRG2c
and proNRGLinker present in these transfectants were anal-
ogous to those found in 293 cells, i.e., with the immature
form predominating in the proNRGLinker mutant (Figure
6A). In addition, the truncated tail fragments were difficult
to detect in MCF7-NRGLinker cells.
We investigated the growth properties of MCF7, MCF7-
NRG2c, and MCF7-NRGLinker cells. As shown in Figure
6B, MCF7-NRG2c cells proliferated to higher densities than
parental MCF7 cells. Addition of soluble NRG stimulated
parental MCF7 proliferation to levels analogous to those
obtained by MCF7-NRG2c. As expected, the latter were
insensitive to the addition of exogenous NRG. MCF7-
NRGLinker cells proliferated slightly more than parental
MCF7 cells, but much less than MCF7-NRG2c. This was
not due to a defect of the MCF7-NRGLinker because analo-
gous results were obtained with other MCF7-NRGLinker
clones (data not shown), and addition of soluble NRG
caused this clone to increase MTT uptake to amounts anal-
ogous to those of MCF7-NRG2c cells or MCF7 cells treated
with NRG (Figure 6B).
The low presence of truncated fragments in blots from
cells expressing the proNRGLinker provoked the question of
whether the different biological properties of MCF7-
Figure 7. Uncleavable proNRG2c is active. (A) Reg-
ulated expression of proNRG in MCF7-NRGTetOff cells.
MCF7-NRGTetOff cells cultured in the presence or ab-
sence of doxycycline (10 ng/ml) were analyzed for their
expression by Western blotting with the proNRG anti-
body. (B) The metalloprotease inhibitor BB3103 pre-
vents cleavage of proNRG2c. MCF7-NRGTetOff cells
were treated with or without BB3103 (20 M) overnight,
and expression of proNRG2c was analyzed by immu-
noprecipitation and Western blot as above. On the other
hand the conditioned medium of this experiment was
used to analyze the phosphorylation of ErbB2 by West-
ern blotting in MCF7 cells. (C) MCF7-NRGTetoff or
MCF7Tetoff cells plated in 24-well plates in the presence
or absence of doxycycline (10 ng/ml) were treated with
or without BB3103 (20 M), and MTT uptake was mea-
sured 5 d later. The data represent the mean  SD of
quadruplicates of an experiment that was repeated
twice. (D) Expression of proNRGMKV in MCF7 cells.
The conditioned media from these cells were used to
stimulate MCF7 cells. The extracts were immunopre-
cipitated with anti-ErbB2 antibody, and the blot was
probed with the anti-phosphotyrosine antibody (bot-
tom panel). (E) Production of soluble NRG by MCF7,
MCF7-NRG2c, and MCF7-NRGMKV cells. The media
were concentrated 10-fold, and an aliquot was used for
the Western analysis of soluble NRG production using
the anti-NRG antibody. (F) Proliferation of MCF7,
MCF7-NRG2c, and MCF7-NRGMKV cells. The exper-
imental conditions were as those described for the ex-
periment shown in Figure 6B.
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NRG2c and MCF7-NRGLinker were due to restricted shed-
ding of the proNRGLinker mutant. To test this, conditioned
media from MCF7, MCF7-NRG2c, and MCF7-NRGLinker
were collected and added to serum-starved MCF7 cells, and
ErbB2 tyrosine phosphorylation was analyzed by Western
blotting. Conditioned media from MCF7-NRG2c cells con-
tained soluble NRG, in contrast to media from MCF7-
NRGLinker cells (Figure 6C, top panel). This result indicated
that production of soluble NRG was profoundly compro-
mised in cells expressing the proNRGLinker mutant. Incu-
bation of MCF7 cells with conditioned media from MCF7-
NRG2c caused tyrosine phosphorylation of ErbB2 (Figure
6C, bottom panel). However, incubation with the condi-
tioned media from MCF7-NRGLinker or parental MCF7 cells
did not induce any significant tyrosine phosphorylation
of ErbB2, confirming the poor release of NRG from
proNRGLinker. Analogous data were obtained with condi-
tioned media from 293 cells expressing wild-type proNRG2c
or proNRGLinker (data not shown).
Biological Activity of Cell Surface Transmembrane
pro-NRG Forms
To further evaluate the importance that shedding of proNRG
may have on its action, we used two strategies: 1) we used
BB3103, an hydroxamic acid derivative that prevents
proNRG2c shedding (Montero et al., 2000); and 2) we
studied the biological activity of a proNRG2c mutant
(proNRGMKV) that is highly resistant to shedding (Montero
et al., 2000). For the pharmacological studies and to avoid
clonal differences, we used an MCF7 cell line in which
proNRG2c was expressed in a regulated manner using the
tetracycline transactivator system (Figure 7A). In these cells,
treatment with BB3103 caused accumulation of the full-
length proNRG2c form (Figure 7B, top panel) and pre-
Figure 8. Transmembrane proNRG activates
ErbB receptors in trans. (A) Activation of ErbB
receptors and the Akt route by proNRG2c and
other mutants. MCF7, MCF7-NRG2c, MCF7-
NRGMKV, and MCF7-NRGLinker cells were
lysed and immunoprecipitated with anti-ErbB2,
anti-ErbB3, or anti-ErbB4 antibodies. Western
blot was performed with anti-phosphotyrosine
antibodies. One part of the cellular extract was
analyzed by Western blot with the anti-pAkt
antibody. As a loading control a blot with anti-
actin was performed. (B) Phosphorylation of
ErbB2 at different tyrosine residues. MCF7,
MCF7-NRG2c, MCF7-NRGMKV, and MCF7-
NRGLinker cells were lysed and immunopre-
cipitated with anti-ErbB2 antibodies. Blots were
probed with antibodies specific for ErbB2,
pTyr1248, pTyr1221/1222, pTyr1139, and pTyr877 of
ErbB2. The BT474 cell line was used as a control.
(C) Analysis of the subcellular distribution of
pY1139-ErbB2 by immunofluorescence micros-
copy. The different cell lines were plated on
coverslips and analyzed with anti-ErbB2 or
anti-pErbB2-Tyr1139 antibodies. (D) 293, 293-
NRG2c, or 293-NRGMKV cells were coincu-
bated with MCF7 cells for 30 min, and the phos-
phorylation of ErbB2 analyzed by Western
blotting as described above. (E) Coincubation
experiment analogous to that presented in D, by
using TACEZn/Zn or TACEZn/Zn-NRG2c
cells with MCF7 cells.
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vented ErbB2 tyrosine phosphorylation caused by the con-
ditioned media from these cells (Figure 7B, bottom panel).
Repression of proNRG2c caused a strong decrease in the
proliferation of MCF7-NRGTetOff cells (Figure 7C), and treat-
ment with BB3103 did not have any detectable effect on the
ability of transfected transmembrane proNRG2c to in-
crease MTT uptake. Western blotting of proNRG2c indi-
cated that the drug was active throughout the length of the
experiment (data not shown).
We also used MCF7 cells expressing proNRGMKV, a mu-
tant that is correctly targeted to the plasma membrane (see
Figure 5, B and C). MCF7-NRGMKV cells contained very
small amounts of cell-bound truncated fragments (Figure
7D, top panel). The latter reflected poor release of NRG, as
also demonstrated by Western blotting of conditioned media
(Figure 7E). This restricted cleavage was also indicated by
the failure of conditioned media from MCF7-NRGMKV cells
to stimulate tyrosine phosphorylation of ErbB2 (Figure 7D,
bottom panel). Analysis of the growth properties of MCF7-
NRGMKV cells indicated that their growth was analogous
to that of MCF7-NRG2c cells and could not be further
increased upon exogenous NRG treatment (Figure 7F).
These results suggested that even though shedding of the
MKV mutant was profoundly compromised, the transmem-
brane factor may retain biological activity.
Transmembrane proNRG Forms Cause Constitutive
Activation of ErbB-dependent Signaling Pathways
Immunoprecipitation with anti-ErbB2 antibodies, followed
by Western blotting with anti-phosphotyrosine, indicated
that ErbB2 was phosphorylated in cells that expressed
proNRG2c or proNRGMKV, but not in cells expressing the
proNRGLinker mutant (Figure 8A). Analogous results were
obtained when analyzing the tyrosine phosphorylation sta-
tus of ErbB3 and ErbB4. Western analyses of signaling mol-
ecules that have been implicated in ErbB mitogenic signaling
indicated constitutive phosphorylation of Akt in cells ex-
pressing proNRG2c or proNRGMKV (Figure 8A). There-
fore, it is likely that intracellular forms of proNRG may be
unable to activate ErbB receptors, in contrast to cell surface–
exposed forms.
We analyzed the subcellular distribution of tyrosine-phos-
phorylated ErbB2 by immunofluorescence microscopy. To
this end, we used a panel of antibodies directed to different
phosphospecific sites within ErbB2. These antibodies were
first tested in Western using as a control BT474 cells, in
which ErbB2 is constitutively phosphorylated due to over-
expression (e.g., see Lane et al., 2000; Agus et al., 2002; Yuste
et al., 2005). As shown in Figure 8B, all the phosphorylation
site–specific antibodies reacted with ErbB2 from BT474 cells.
The antibody identifying pY1248 reacted poorly with ErbB2
receptors from MCF7-NRG2c and MCF7-NRGMKV. Much
better signals were obtained by using the antibodies that
recognized pY1221/1222, pY1139, or pY877. In terms of
signal intensity, the immunofluorescence analyses using
these antibodies correlated with the Western blotting results,
i.e., the anti-pY1248 gave a poor signal, and the best stain-
ings were obtained with the anti-pY1139 and the anti-pY877
antibodies (data not shown). In BT474 cells, the anti-pY1139
uniformly stained the cell surface (Figure 8C), indepen-
dently of whether cell–cell contacts were established or not.
This is indicative of activation of ErbB2 by increased oli-
gomerization frequency due to overexpression, a mecha-
nism of activation that is ligand-independent (Ullrich and
Schlessinger, 1990). In MCF7-NRG2c and MCF7-NRGMKV
cells, most of the anti-pErbB2 signal accumulated at cell–cell
contact sites (Figure 8C). Very little immunofluorescent sig-
nal was present in cultures of MCF7 or MCF7-NRGLinker
cells using these anti-pErbB2 antibodies.
The staining pattern at cell–cell contact sites in MCF7-
NRG2c and MCF7-NRGMKV cells suggested that trans-
membrane NRG could activate ErbB receptors in trans. To
explore this possibility, we cocultured 293 cells expressing
proNRG2c or proNRGMKV, with MCF7 cells. Because 293
cells do not respond to NRG, any change in tyrosine phos-
phorylation of ErbB receptors must correspond to the recep-
tors expressed by MCF7 cells. Coincubation of MCF7 cells
with 293-proNRG2c, or 293-proNRGMKV cells caused
stimulation of ErbB2, ErbB3, and ErbB4 receptors expressed
by MCF7 cells (Figure 8D). It should be mentioned that the
ability of the 293-proNRGMKV cells to stimulate the ty-
rosine phosphorylation of these receptors was below that
induced by the 293-proNRG2c cells. We also performed
analogous coculture experiments using TACEZn/Zn cells
expressing proNRG2c (TACEZn/Zn-NRG2c). TACEZn/Zn
cells were isolated from mice on which the Zinc-binding
region of the protease TACE was deleted by homologous
recombination (Peschon et al., 1998). As a consequence, the
protease is inactive and fails to cleave multiple membrane-
bound proteins (Peschon et al., 1998), including proNRG2c
(Montero et al., 2000). Coincubation of MCF7 cells with
TACEZn/Zn-NRG2c provoked tyrosine phosphorylation
of ErbB2 (Figure 8E). However, when MCF7 cells were co-
incubated with TACEZn/Zn cells, that we used as a con-
trol, no significant increase in tyrosine phosphorylation of
ErbB2 was detected.
DISCUSSION
The extracellular linker of membrane-anchored growth fac-
tors is the region where surface proteases act to release
soluble forms of these factors. Based on this, the linker has
been considered a critical region for the regulation of the
balance between the soluble and transmembrane forms of
membrane-anchored polypeptide factors. Here we show
that this region is also required for adequate sorting of
proNRG2c to the plasma membrane. Furthermore, we
show that a discrete mutation of the linker that does no affect
cell surface sorting, but that impairs cleavage, is active,
demonstrating that transmembrane proNRGs retain at least
part of their biological properties. Thus, our data suggest
that the linker may represent more than a mere region where
cleavage occurs and indicate that this zone plays multiple
functions in the biology of membrane-anchored growth fac-
tors.
Multiple molecular forms of proNRG2c (p80, p72, and
p70), together with some C-terminal cell bound fragments
were identified. In pulse-chase experiments, the p70 and p72
forms appeared shortly after the start of the metabolic label-
ing and chased into the p80 form, suggesting that p70 and
p72 are precursors of p80. Why two precursor forms are
present instead of only one is yet unclear, but may indicate
differential states of glycosylation of p70 and p72 in the
initial steps of proNRG2c biosynthesis. p70 and p72 may
later gain additional posttranslational modifications, proba-
bly complex sugars, during their movement through intra-
cellular compartments. The diffuse nature of the p80 band in
Western blots may thus be a reflection of the sum of several
heterogeneously glycosylated forms, p70 and p72 being the
predominant precursors.
The subcellular location of the p80 form was distinct from
that of the p70/p72 forms. p80 was present at the plasma
membrane, whereas p70/p72 located intracellularly. Al-
though p80 and p72 were sensitive to tunicamycin, only the
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latter was affected by Endo H. These data indicate that both
p80 and p72 contain N-linked sugars and differentiate both
proNRG2c forms in their location, because Endo H attacks
sugar chains at the cis-Golgi and previous compartments of
the secretory pathway. Therefore, p72 must be a precursor
form that has not yet escaped from the ER or, most likely,
the cis-Golgi. Less obvious is the nature of p70. The latter
form was apparently insensitive to tunicamycin or Endo H,
indicating that p70 does not contain N-linked sugars or is
not glycosylated at all. However, because this form was
resistant to proteinase K, was not biotinylated, and could not
be precipitated in cell surface immunoprecipitation experi-
ments, we conclude that this form is not exposed at the cell
surface and locates in a compartment of the secretory path-
way.
The candidate compartment where p70 and p72 may re-
side is the Golgi, because most intracellular staining using
the anti-proNRG antibody was coincident with the cis-Golgi
marker GM130. The fact that p70/p72 were located at this
compartment indicates that exit from the Golgi may repre-
sent a rate-limiting step in the sorting of proNRG2c. This
is further supported by the enhanced entrapment of
proNRGLinker at this compartment. Although checkpoint
controls have been well defined at the ER (Kleizen and
Braakman, 2004), the presence of such controls at the Golgi
apparatus has been less studied (Ellgaard and Helenius,
2003). However, evidence exists indicating that luminal
(Yeaman et al., 1997; Gut et al., 1998), cytosolic (Wahlberg et
al., 1995; Stockklausner and Klocker, 2003; Hofherr et al.,
2005), or transmembrane (Kundu et al., 1996) determinants
may control sorting from the Golgi. In the case of
proNRG2c, the linker sequence deleted does not contain
any N-linked glycosylation consensus site and only includes
a threonine that could act as an O-glycosylation site. How-
ever, this site has not been reported to be glycosylated
(Burgess et al., 1995). Furthermore, the conservation of this
threonine in mutants of the linker in which defective sorting
occurs argues against the potential role of this residue in
glycosylation-dependent sorting. Moreover, treatment with
tunicamycin to prevent N-linked glycosylation in vivo did
not affect surface exposure of proNRG2c. In addition, the
pulse-chase metabolic labeling and the brefeldin A experi-
ments showed that in the initial steps of their biosynthesis
proNRG2c and proNRGLinker behaved analogously, indi-
cating that the defect in the sorting of the latter must occur
at a step beyond the biosynthesis and the cotranslational
N-linked addition of sugars in the ER.
An open question is how deletions in the linker affect
sorting. A possible scenario could be that of a Golgi check-
point system that detects altered proNRG and prevents its
sorting probably by interaction with resident Golgi proteins.
It is worth mentioning that the proNRGIg mutant efficiently
sorted to the plasma membrane. This indicates that the mere
deletion of a random extracellular sequence cannot provoke
intracellular retention and opens the possibility that a spe-
cific sequence in the linker could be required for efficient
sorting. However, more subtle deletions both at the N-ter-
minus or the C-terminus of the linker caused a phenotype
analogous to deletion of the whole linker. In addition, sub-
stitution of the proNRG2c linker by unrelated sequences,
but preserving the length of the linker, created chimeric
proteins that were efficiently transported to the surface.
These data suggest that the linker may act as a spacer
between the transmembrane domain and the rest of the
extracellular domain and suggest that maintenance of a
spacing between these regions may be required for efficient
delivery of proNRG2c to the plasma membrane. In addi-
tion to this domain, it is possible that other regions of
proNRGs may be involved in membrane anchoring and
plasma membrane sorting. In the case of the related mem-
brane factor proTGF, deletions of the intracellular cytosolic
tail prevented its sorting to the plasma membrane (Briley et
al., 1997; Fernandez-Larrea et al., 1999). As a result, proTGF
was deficiently cleaved and release of soluble factor was
prevented (Bosenberg et al., 1992; Briley et al., 1997).
Another conclusion that can be obtained from our stud-
ies is the clear dissection between efficient sorting of
proNRG2c and its membrane association. In this respect,
membrane association of proNRGLinker was undistinguish-
able from that of the wild type, as indicated by cell fraction-
ation. Therefore, the linker is not critical for proNRG2c
membrane association.
In addition to the defect in sorting, deletions in the linker
altered the biological properties of membrane-bound
proNRG2c. Deletions that resulted in intracellular entrap-
ment of proNRG created a transmembrane form that was
inactive. This was interesting because intracellular EGF
stimulates the EGF receptor inside the cell (Wiley et al., 1998;
Dong et al., 2005). In our experimental system, the
proNRGLinker form was unable to cause stimulation of
ErbB receptors. To explain this, several possible situations
were contemplated, including defective cleavage or intracel-
lular entrapment. Our data suggest that membrane-an-
chored proNRG2c retains biological activity. Thus, expres-
sion in MCF7 cells of the proNRGMKV mutant, in which
cleavage is profoundly impaired, resulted in proliferation
rates at least as good as those obtained by MCF7-NRG2c
cells. Analogous results were reported for HB-EGF, a related
EGF family transmembrane factor, on which deletion of five
amino acids of the linker also prevented cleavage without
affecting its juxtacrine action (Singh et al., 2004). Biochemi-
cally, membrane-bound proNRG provoked tyrosine phos-
phorylation of the ErbB receptors, and this appeared to be
due to activation in trans, although our data cannot exclude
that activation of ErbB receptors may also occur in cis. In
fact, coincubation of 293-proNRGMKV cells with MCF7 cells
caused tyrosine phosphorylation of ErbB2, ErbB3, and
ErbB4. In addition, analogous results were obtained in co-
cultures of MCF7 cells with TACEZn/Zn-NRG2c cells.
Finally, immunofluorescence analyses of MCF7 cells ex-
pressing proNRG2c or proNRGMKV using anti-p-ErbB2
antibodies indicated that tyrosine-phosphorylated forms of
ErbB2 accumulated at the sites of cell–cell contact. Clearly,
the interaction in trans opens the interesting structural ques-
tion of how ErbB receptors from a cell may interact with
membrane-bound factors presented by another neighboring
cell. The structures of soluble NRG with the ectodomain of
ErbB receptors have been solved (reviewed in Burgess et al.,
2003), but they do not clearly address how a transmembrane
ligand may be able to activate the receptors present in neigh-
boring cells. What can be postulated is that for this interac-
tion to occur it is likely that a substantial degree of flexibility
of both the ligand and the receptor must be required. Be-
cause cleavage appeared to be dispensable for proNRG ac-
tivity, the failure of the proNRGLinker mutant to stimulate
ErbB receptors or cell proliferation may be caused by its
intracellular entrapment. Obviously, an additional possibil-
ity could be that of inability to activate ErbB receptors by
steric reasons in the case of proNRGLinker.
Given the different experimental data obtained using dis-
tinct membrane-anchored growth factors and model sys-
tems, it appears risky to generalize with respect to the ability
of these factors to be biologically functional in their trans-
membrane conformation. Rather, a more precise view may
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be one that considers different possible variables, such as the
type of the membrane-bound factor and the cellular context,
that in concert may explain the capabilities of the factors to
act in a juxtacrine mode or not. Other concepts that must be
clearly dissociated are those that refer to the physiological
importance of shedding versus the capability of a membrane
factor to be biologically active. Obviously, animal studies in
mice indicate that shedding of membrane proteins is critical
for animal development (Peschon et al., 1998; Hartmann et
al., 2002; Sahin et al., 2004). This could be due to the fact that
soluble forms of membrane factors may be required at sites
distant from the cells that produce these factors. However,
this property does not negate the concept that membrane-
bound forms of growth factors may be biologically active, as
far as the receptors for these factors are present in cells that
are in physical contact with the cells that produce the factor.
The development of additional in vitro and in vivo models
to address these questions is an important challenge for
studies in the area of membrane-anchored growth factor
physiology and pathology.
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